Innate Pharma reveals promising results for SAR443579/IPH6101 in blood cancers

Innate Pharma SA announced new efficacy and safety results for SAR443579/IPH6101, an NK Cell Engager in development with Sanofi. At the European Hematology Association, data showed complete remissions in patients with relapsed or refractory acute myeloid leukemia.

SAR443579/IPH6101, targeting CD123 and engaging NKp46/CD16 receptors, demonstrated durable clinical responses. Complete remissions were observed at a dose of 1 mg/kg, some lasting more than 10 months. Sanofi is leading this Phase 1/2 trial, which will advance to Phase 2 with defined recommended doses.

Fifty-nine patients were treated, showing a maximal response rate with well-tolerated weekly doses of 6 mg/kg. The collaboration between Innate Pharma and Sanofi continues to progress, aiming to prove the potential of this innovative treatment for hematological cancers.